ArticleAMB Express2026
Lactiplantibacillus plantarum P16 mitigated murine colitis through modulation of immune response and gut microbiota.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Probiotics show potential for preventing and mitigating inflammatory bowel disease (IBD), though their efficacy and mechanisms are strain-specific. This study aimed to elucidate the protective mechanism of Lactiplantibacillus (L.) plantarum P16 against dextran sulfate sodium (DSS)-induced ulcerative colitis (UC). The strain exhibited high gastrointestinal tolerance, with survival rates of approximately 86% in artificial gastric fluid (pH 3.0) and 94% in 0.3% bile salt after 3 h of incubation. Moreover, L. plantarum P16 showed stronger adhesion to Caco-2 cells, indicating a high potential for intestinal colonization. In a DSS-induced colitis model, L. plantarum P16 administration alleviated colitis by reducing the disease activity index (DAI), suppressing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and mitigating colonic tissue damage while preserving epithelial barrier integrity. Additionally, L. plantarum P16 treatment increased short-chain fatty acid (SCFA) levels. 16 S rRNA amplicon sequencing of cecal content revealed that L. plantarum P16 supplementation restored gut microbial homeostasis by elevating the abundances of Firmicutes and Verrucomicrobiota, particularly Akkermansia, while reducing the proportions of Bacteroides and Helicobacter. These findings demonstrated that L. plantarum P16 could alleviate colitis by ameliorating intestinal inflammation and restoring gut microbiota dysbiosis, proposing a novel perspective of L. plantarum P16 for UC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.